Omentum: Friend or foe in ovarian cancer immunotherapy?-Reference-Cited by-同舟云学术

Omentum: Friend or foe in ovarian cancer immunotherapy?

Published:2022 Issue: Volume: Page:117-131
ISSN:1937-6448
Container-title:International Review of Cell and Molecular Biology
language:
Short-container-title:

Author:

Bella Ángela,Arrizabalaga Leire,Di Trani Claudia Augusta,Fernández-Sendin Myriam,Teijeira Alvaro,Russo-Cabrera Joan Salvador,Melero Ignacio,Berraondo Pedro,Aranda Fernando

Funder

European Regional Development Fund

H2020 Marie Skłodowska-Curie Actions

Instituto de Salud Carlos III

European Social Fund

Horizon 2020

Publisher

Elsevier

Reference73 articles.

1. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J. Clin. Oncol.,2012

2. Ovarian Cancer;Arora,2021

3. Omentum Tumors;Bahar,2021

4. Transforming growth factor-beta signaling in immunity and cancer;Batlle;Immunity,2019

5. The greater omentum: physiology and immunological concepts;Beelen;Neth. J. Surg.,1991

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Morphological differences between the lesser and the greater omenta in albino rats;Annals of Anatomy - Anatomischer Anzeiger;2024-10

2. Morphofunctional Differences between the Lesser and the Greater Omenta in Albino Rats;2024

3. Peritoneal carcinomatosis in mouse models;Methods in Cell Biology;2024

4. Research progress of Astragalus membranaceus in treating peritoneal metastatic cancer;Journal of Ethnopharmacology;2023-04

5. Myeloid-derived suppressor cells: Emerging players in cancer and beyond;Myeloid-derived suppressor cells;2023